arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Kodiak Sciences Inc

KOD Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$85.78
▼ -7.7% Today
as of Oct 22, 16:49 ET
Last 30 days +158.84% Sep 14 → Oct 22
$26.05 $45.87 $65.70 $85.52 $105.34 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$87.14
High
$89.52
Low
$84.86
Volume
$593,436
Avg Vol
$1M
Mkt Cap
$6.2B
P/E (TTM)
—
Beta
—
52w High
$104.00
52w Low
$15.83
Div Yield
—
Shares Out
$63M

Recent Press Releases & News last 60 days · 25 items

Oct 19 · 12:10 Zacks
Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?
Oct 8 · 19:12 Simply Wall St.
Kodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data Update
Oct 8 · 15:13 Simply Wall St.
Kodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial News
▸ Show all 25 press releases & news Free account →

KOD earnings at a glance

The options market is pricing a move of about ±9.4% after the report, a range of roughly $77.74 to $93.82 from today's $85.78. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±3.5% on average; after the most recent report on May 7, 2026 it moved -4.8%. That means options currently expect more movement than KOD has typically delivered. KOD beat the consensus EPS estimate in 0 of its last 4 reported quarters. Implied volatility is currently 79%. The share price of $85.78 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$16
$104
79% of range
Avg surprise (last 4)
-8.5%
Avg reaction (last 2)
-3.5%
0% positive
Latest IV / EM
79%
EM ±9.4% · $95 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.53$-1.35$-1.18$-1.00$-0.82 Actual $-1.35Actual $-1.53Actual $-0.95Actual $-0.82Actual $-0.86Actual $-0.84Actual $-1.09Est $-0.89Actual $-1.03Est $-1.01Actual $-1.16Est $-1.07Actual $-0.94Est $-0.93Actual $-1.05 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-66M$-61M$-56M$-51M$-46M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.05 — — — — financials
Thu May 7, 2026Mar/2026 $-0.94 $-0.93 -1.1% +13.8% -4.8% earnings
Thu Nov 13, 2025Sep/2025 $-1.16 $-1.07 -8.4% — — earnings
Wed Aug 13, 2025Jun/2025 $-1.03 $-1.01 -2.0% — — earnings
Wed May 14, 2025Mar/2025 $-1.09 $-0.89 -22.5% — -2.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.84 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.86 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.82 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.95 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.53 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.35 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-67M$-60M—$-62M$-56M$-59M—$-47M
Net income$-66M$-58M—$-61M$-54M$-57M—$-44M
EPS (diluted)$-1.05$-0.94—$-1.16$-1.03$-1.09—$-0.84

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$126M$170M$210M$72M$104M$139M$168M$198M
Inventory————————
Total current assets$131M$175M$215M$76M$108M$143M$172M$202M
Total assets$257M$306M$352M$218M$257M$298M$336M$373M
Long-term debt————————
Total liabilities$196M$194M$194M$194M$186M$189M$185M$187M
Total equity$61M$112M$157M$24M$70M$109M$150M$185M

Implied volatility — last 90 days

69%116%164%211%259% Jun 07 — IV 96% · EM ±13.4%Jun 08 — IV 96% · EM ±12.7%Jun 09 — IV 82% · EM ±10.3%Jun 10 — IV 87% · EM ±10.3%Jun 11 — IV 90% · EM ±9.9%Jun 12 — IV 81% · EM ±8.3%Jun 15 — IV 89% · EM ±6.5%Jun 16 — IV 145% · EM ±8.6%Jun 17 — IV 159% · EM ±6.7%Jun 19 — IV 80% · EM ±17.8%Jun 22 — IV 79% · EM ±16.5%Jun 23 — IV 93% · EM ±19.0%Jun 24 — IV 84% · EM ±16.7%Jun 25 — IV 78% · EM ±15.2%Jun 26 — IV 78% · EM ±14.9%Jun 29 — IV 84% · EM ±14.9%Jun 30 — IV 83% · EM ±14.3%Jul 01 — IV 87% · EM ±14.6%Jul 02 — IV 88% · EM ±14.3%Jul 03 — IV 91% · EM ±14.3%Jul 06 — IV 89% · EM ±12.4%Jul 07 — IV 82% · EM ±10.8%Jul 08 — IV 82% · EM ±10.3%Jul 09 — IV 81% · EM ±9.5%Jul 10 — IV 126% · EM ±13.9%Jul 13 — IV 157% · EM ±13.1%Jul 14 — IV 126% · EM ±9.1%Jul 15 — IV 166% · EM ±9.8%Jul 16 — IV 260% · EM ±10.8%Jul 20 — IV 111% · EM ±26.2%Jul 21 — IV 100% · EM ±23.2%Jul 22 — IV 102% · EM ±23.4%Jul 23 — IV 101% · EM ±22.7%Jul 24 — IV 91% · EM ±20.2%Jul 27 — IV 106% · EM ±22.1%Jul 28 — IV 104% · EM ±21.3%Jul 29 — IV 102% · EM ±20.4%Jul 30 — IV 101% · EM ±19.8%Jul 31 — IV 102% · EM ±19.5%Aug 03 — IV 107% · EM ±19.0%Aug 04 — IV 101% · EM ±17.4%Aug 05 — IV 116% · EM ±19.4%Aug 06 — IV 97% · EM ±15.6%Aug 07 — IV 105% · EM ±16.4%Aug 10 — IV 126% · EM ±17.5%Aug 11 — IV 108% · EM ±14.3%Aug 12 — IV 119% · EM ±14.9%Aug 13 — IV 98% · EM ±11.6%Aug 14 — IV 90% · EM ±9.9%Aug 17 — IV 102% · EM ±8.5%Aug 18 — IV 105% · EM ±7.6%Aug 19 — IV 131% · EM ±7.7%Aug 20 — IV 141% · EM ±5.9%Aug 24 — IV 87% · EM ±18.3%Aug 25 — IV 78% · EM ±16.0%Aug 26 — IV 78% · EM ±15.7%Aug 27 — IV 69% · EM ±13.5%Aug 28 — IV 89% · EM ±17.1%Aug 31 — IV 88% · EM ±15.5%Sep 01 — IV 83% · EM ±14.4%Sep 02 — IV 95% · EM ±15.9%Sep 03 — IV 99% · EM ±16.0%Sep 04 — IV 97% · EM ±15.2%Sep 07 — IV 110% · EM ±15.2%Sep 08 — IV 86% · EM ±11.3%Sep 09 — IV 109% · EM ±13.6%Sep 10 — IV 129% · EM ±15.2%Sep 11 — IV 111% · EM ±12.3%Sep 14 — IV 81% · EM ±6.8%Sep 15 — IV 120% · EM ±8.7%Sep 16 — IV 154% · EM ±9.1%Sep 17 — IV 184% · EM ±7.7%Sep 21 — IV 237% · EM ±49.5%Sep 22 — IV 238% · EM ±48.7%Sep 23 — IV 247% · EM ±49.5%Sep 24 — IV 243% · EM ±47.6%Sep 25 — IV 254% · EM ±48.5%Sep 28 — IV 151% · EM ±26.7%Sep 29 — IV 103% · EM ±17.8%Sep 30 — IV 85% · EM ±14.2%Oct 01 — IV 76% · EM ±12.2%Oct 02 — IV 78% · EM ±12.2%Oct 06 — IV 84% · EM ±11.1%Oct 07 — IV 70% · EM ±8.8%Oct 08 — IV 79% · EM ±9.4%

Sector peers

CGON
CG Oncology, Inc.
$6.1B $62.54+1.0%
IOVA
Iovance Biotherapeutics, Inc.
$5.9B $14.14-4.8%
SRRK
Scholar Rock Holding Corporation
$5.6B $41.96+1.4%
IMVT
Immunovant, Inc.
$7.0B $29.10+1.8%
CRSP
CRISPR Therapeutics AG
$5.4B $49.99+0.2%
RGEN
Repligen Corporation
$8.2B $178.71-0.1%

KOD earnings FAQ

What is KOD's expected move for earnings?

Options currently price a move of about ±9.4%, or $8.04 per share either way from $85.78.

How does KOD stock usually react to earnings?

Across the last 2 reports the average next-day move was ±3.5%, up 0 times and down 2 times.

What is KOD's implied volatility?

KOD's at-the-money implied volatility is about 79% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in